Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection (Q42255783)

19 October 2017

title

Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection (English)

1 reference

19 October 2017

5

1 reference

19 October 2017

G Pasquale

3

0 references

Caterina Sagnelli

object named as

C Sagnelli

1

0 references

Caterina Uberti-Foppa

object named as

C Uberti-Foppa

2

0 references

Evangelista Sagnelli

object named as

E Sagnelli

9

0 references

author name string

S De Pascalis

4

1 reference

19 October 2017

L Albarello

6

1 reference

19 October 2017

C Doglioni

7

1 reference

19 October 2017

A Lazzarin

8

1 reference

19 October 2017

publication date

10 July 2013

1 reference

19 October 2017

1 reference

19 October 2017

volume

41

1 reference

19 October 2017

issue

5

1 reference

19 October 2017

page(s)

959-967

1 reference

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Development of hepatotoxicity in HIV patients switching at least one protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

The natural history of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Chronic hepatitis C: beware the older drinking male: fibrosis progression beckons!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0502-3

Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C

1 reference

12 December 2020

Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.

1 reference

12 December 2020

HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.

1 reference

12 December 2020

10.1007/S15010-013-0502-3

Identifiers

DOI

1 reference

19 October 2017

1 reference